Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIQ

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIQ - Post by User

IMV Inc > So... is this enough to move forward or not?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(43)
•••
Comment by Breakthorough1on May 29, 2020 3:40pm
199 Views
Post# 31089528

RE:So... is this enough to move forward or not?

RE:So... is this enough to move forward or not?What F. Ors said in the CC in february was that the FED was going to say ok to anything with +20% ORR, good safety profile and +6months MDOR ("Median duration of response"). So Survivac is in the numbers. Does anyone know exactly hoy the 7.9 months of MDOR of PARP inhibitors were calculated? Did it included only the PRs or also the SD (so, the whole DCR)?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities